BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 36727544)

  • 1. Incidence and risk factors for second malignancies among patients with myeloproliferative neoplasms.
    Zhang Y; Han Y; Teng G; Du C; Gao S; Yuan W; Zhang L; Bai J
    Cancer Med; 2023 Apr; 12(8):9236-9246. PubMed ID: 36727544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival patterns in United States (US) medicare enrollees with non-CML myeloproliferative neoplasms (MPN).
    Price GL; Davis KL; Karve S; Pohl G; Walgren RA
    PLoS One; 2014; 9(3):e90299. PubMed ID: 24618579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Classic myeloproliferative neoplasms in Singapore: A population-based study on incidence, trends, and survival from 1968 to 2017.
    Htun HL; Lian W; Wong J; Tan EJ; Foo LL; Ong KH; Lim WY
    Cancer Epidemiol; 2022 Aug; 79():102175. PubMed ID: 35569302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myeloproliferative neoplasms (MPNs) have a significant impact on patients' overall health and productivity: the MPN Landmark survey.
    Mesa R; Miller CB; Thyne M; Mangan J; Goldberger S; Fazal S; Ma X; Wilson W; Paranagama DC; Dubinski DG; Boyle J; Mascarenhas JO
    BMC Cancer; 2016 Feb; 16():167. PubMed ID: 26922064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term outcome of liver transplant patients with Budd-Chiari syndrome secondary to myeloproliferative neoplasms.
    Potthoff A; Attia D; Pischke S; Mederacke I; Beutel G; Rifai K; Deterding K; Heiringhoff K; Klempnauer J; Strassburg CP; Manns MP; Bahr MJ
    Liver Int; 2015 Aug; 35(8):2042-9. PubMed ID: 25736096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
    Duangnapasatit B; Rattarittamrong E; Rattanathammethee T; Hantrakool S; Chai-Adisaksopha C; Tantiworawit A; Norasetthada L
    Asian Pac J Cancer Prev; 2015; 16(12):5013-8. PubMed ID: 26163633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thrombosis among 1537 patients with JAK2
    Zhang Y; Zhou Y; Wang Y; Teng G; Li D; Wang Y; Du C; Chen Y; Zhang H; Li Y; Fu L; Chen K; Bai J
    Cancer Med; 2020 Mar; 9(6):2096-2105. PubMed ID: 31994332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mortality outcomes and survival patterns of patients with myeloproliferative neoplasms in Malaysia.
    Yap YY; Sathar J; Law KB;
    Cancer Causes Control; 2022 Feb; 33(2):343-351. PubMed ID: 34846616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of disease transformation and second primary solid tumors in patients with myeloproliferative neoplasms.
    Hong J; Lee JH; Byun JM; Lee JY; Koh Y; Shin DY; Lee JO; Hwang SM; Choi HS; Kim I; Yoon SS; Bang SM
    Blood Adv; 2019 Nov; 3(22):3700-3708. PubMed ID: 31765478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bleeding complications in bcr-abl-negative myeloproliferative neoplasms (MPN): A retrospective single-center study of 829 MPN patients.
    Wille K; Huenerbein K; Jagenberg E; Sadjadian P; Becker T; Kolatzki V; Meixner R; Marchi H; Fuchs C; Griesshammer M
    Eur J Haematol; 2022 Feb; 108(2):154-162. PubMed ID: 34719056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical Analysis of 208 Patiets with BCR/ABL Negative Myeloproliferative Neoplasms].
    Shen QH; Guo YJ; Xue CE; Wang Y; Lin FR
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Feb; 27(1):159-164. PubMed ID: 30738463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms.
    Boddu P; Masarova L; Verstovsek S; Strati P; Kantarjian H; Cortes J; Estrov Z; Pierce S; Pemmaraju N
    Ann Hematol; 2018 Jan; 97(1):109-121. PubMed ID: 29143068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Age-related macular degeneration and myeloproliferative neoplasms - A common pathway.
    Liisborg C
    Acta Ophthalmol; 2022 Oct; 100 Suppl 271(Suppl 271):3-35. PubMed ID: 36200281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myeloproliferative neoplasms: trends in incidence, prevalence and survival in Norway.
    Roaldsnes C; Holst R; Frederiksen H; Ghanima W
    Eur J Haematol; 2017 Jan; 98(1):85-93. PubMed ID: 27500783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms in the United States, 2001-12.
    Srour SA; Devesa SS; Morton LM; Check DP; Curtis RE; Linet MS; Dores GM
    Br J Haematol; 2016 Aug; 174(3):382-96. PubMed ID: 27061824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebral vein thrombosis in patients with Philadelphia-negative myeloproliferative neoplasms. An European Leukemia Net study.
    Martinelli I; De Stefano V; Carobbio A; Randi ML; Santarossa C; Rambaldi A; Finazzi MC; Cervantes F; Arellano-Rodrigo E; Rupoli S; Canafoglia L; Tieghi A; Facchini L; Betti S; Vannucchi AM; Pieri L; Cacciola R; Cacciola E; Cortelezzi A; Iurlo A; Pogliani EM; Elli EM; Spadea A; Barbui T
    Am J Hematol; 2014 Nov; 89(11):E200-5. PubMed ID: 25042466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Second malignancies in patients with myeloproliferative neoplasms: a population-based cohort study of 9379 patients.
    Landtblom AR; Bower H; Andersson TM; Dickman PW; Samuelsson J; Björkholm M; Kristinsson SY; Hultcrantz M
    Leukemia; 2018 Oct; 32(10):2203-2210. PubMed ID: 29535425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myeloproliferative neoplasms in the young: Mayo Clinic experience with 361 patients age 40 years or younger.
    Szuber N; Vallapureddy RR; Penna D; Lasho TL; Finke C; Hanson CA; Ketterling RP; Pardanani A; Gangat N; Tefferi A
    Am J Hematol; 2018 Dec; 93(12):1474-1484. PubMed ID: 30157297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression.
    Hahm C; Huh HJ; Mun YC; Seong CM; Chung WS; Huh J
    Int J Lab Hematol; 2015 Apr; 37(2):181-9. PubMed ID: 24845343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry.
    Kaifie A; Kirschner M; Wolf D; Maintz C; Hänel M; Gattermann N; Gökkurt E; Platzbecker U; Hollburg W; Göthert JR; Parmentier S; Lang F; Hansen R; Isfort S; Schmitt K; Jost E; Serve H; Ehninger G; Berdel WE; Brümmendorf TH; Koschmieder S;
    J Hematol Oncol; 2016 Mar; 9():18. PubMed ID: 26944254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.